Defence Therapeutics Inc. (CSE:DTC)
Canada
· Delayed Price · Currency is CAD | Market Cap | 51.60M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.62M |
| Shares Out | 57.33M |
| EPS (ttm) | -0.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,600 |
| Average Volume | 88,159 |
| Open | 0.900 |
| Previous Close | 0.900 |
| Day's Range | 0.860 - 0.900 |
| 52-Week Range | 0.490 - 1.660 |
| Beta | 1.34 |
| RSI | 55.91 |
| Earnings Date | Nov 12, 2025 |
About Defence Therapeutics
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; the anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; the ARM-X ... [Read more]
Financial Performance
Financial StatementsNews
Defence Therapeutics Announces Formation of Scientific Advisory Board to Guide Advancement of Accum-Enhanced Antibody Drug Conjugate Programs
Montreal, Quebec--(Newsfile Corp. - December 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary int...
Defence Therapeutics Announces Convertible Debenture Conversion
Montreal, Quebec--(Newsfile Corp. - November 21, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-ge...
Defence Therapeutics to Build ADC Drug Delivery Powerhouse Using Its Proprietary Accum Technology
Montreal, Quebec--(Newsfile Corp. - November 19, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-ge...
Defence Announces Successful Presentation at the World ADC Conference in San Diego and Plans to Expand Evaluation of Accum in Commercial and Pipeline ADCs
Montreal, Quebec--(Newsfile Corp. - November 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-gen...
Defence Therapeutics Demonstrates Strong Preclinical in Vivo Efficacy Results Evaluating Accum-Kadcyla in Breast Cancer Models
Montreal, Quebec--(Newsfile Corp. - November 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug...
Defence to Present New Scientific Data on Its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025
Montreal, Quebec--(Newsfile Corp. - October 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug...
Defence Therapeutics to Attend CPHI Worldwide in Frankfurt, October 28-30, 2025
Montreal, Quebec--(Newsfile Corp. - October 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug ...
Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations
Montreal, Quebec--(Newsfile Corp. - October 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug ...
Defence's Director, Strategy & Business Advisor Dr. Amie Phinney Discusses the Accum Platform on Money Talk Radio with Ellis Martin
Montreal, Quebec--(Newsfile Corp. - September 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in dr...
Defence Therapeutics Appoints Dr. Amie Phinney as Director
Montreal, Quebec--(Newsfile Corp. - September 16, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in dr...
Defence Therapeutics Completes Fully Subscribed Debenture Units Financing of $2,000,000
Montreal, Quebec--(Newsfile Corp. - September 15, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in dr...
Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next ...
Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth | DTCFF Stock News
IRW-News: Defence Therapeutics Inc.: Defence Therapeutics ernennt Dr. Amie Phinney zur Strategie- und Geschäftsberaterin, um die nächste Wachstumsphase zu begleiten
IRW-PRESS: Defence Therapeutics Inc.: Defence Therapeutics ernennt Dr. Amie Phinney zur Strategie- und Geschäftsberaterin, um die nächste Wachstumsphase zu begleiten
Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth
Montreal, Quebec--(Newsfile Corp. - September 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in dru...
Defence Therapeutics Announces Debenture Units Financing
Montreal, Quebec--(Newsfile Corp. - August 22, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in drug ...
Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer
Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug d...
Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology
Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug de...
IRW-News: Defence Therapeutics Inc.: Defence Therapeutics eröffnet US-Labor im Biotech-Hub Boston-Cambridge • news
IRW-PRESS: Defence Therapeutics Inc.: Defence Therapeutics eröffnet US-Labor im Biotech-Hub Boston-Cambridge
Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub
Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in advanc...
IRW-News: Defence Therapeutics Inc.: Defence Therapeutics nimmt im Juni 2025 an der BIO International Convention in Boston teil • news
IRW-PRESS: Defence Therapeutics Inc.: Defence Therapeutics nimmt im Juni 2025 an der BIO International Convention in Boston teil
Defence Therapeutics to Attend Bio International Convention in Boston, June 2025
Montreal, Quebec--(Newsfile Corp. - May 28, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing advance...
Defence Launches Accum Combined with Actinium-225 to Increase Efficacy and Safety of Radio-Immunoconjugate Cancer Therapies
Montreal, Quebec--(Newsfile Corp. - April 8, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing advanc...
Defence Announces US Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Defence's Management Team as Chief Operating Officer
Montreal, Quebec--(Newsfile Corp. - March 26, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radio...
Defence Closes Second Tranche of Fully Subscribed Financing Totaling $4.2 Million
Montreal, Quebec--(Newsfile Corp. - January 31, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing rad...
Defence to Connect with Industry Leaders and Potential Partners During the JP Morgan Healthcare Conference in San Francisco. Plans to Expand the Next Generation of Radio-Immuno Conjugates in 2025
Montreal, Quebec--(Newsfile Corp. - January 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company") a Canadian biopharmaceutical company developing radi...